SCHEMBL20133128

SCHEMBL20133128

Cn1c2ccncc2c2ccc(-c3ccc(O[C@H]4C[C@H](N(C)C5CCN(C(=O)CCCCOc6ccc7c(c6)C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C4)nc3)cc21

nearest known ligand 0.48

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 13/20 0.48
PLK4 O00444 7/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29547902 0.95 BRD9 (0.49) BRD9PLK4
SCHEMBL20120370 0.95 BRD9 (0.49) BRD9PLK4
SCHEMBL20120372 0.95 BRD9 (0.49) BRD9PLK4
SCHEMBL20133119 0.91 BRD9 (0.46) BRD9
SCHEMBL27138940 0.91 BRD9 (0.45) BRD9
SCHEMBL27098651 0.88 BRD9 (0.43) BRD9
SCHEMBL27150785 0.88 BRD9 (0.43) BRD9
SCHEMBL29857220 0.88 BRD9 (0.43) BRD9
SCHEMBL20120344 0.87 BRD9 (0.44) BRD9
SCHEMBL20120341 0.87 BRD9 (0.44) BRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN BRD9 1284/4885PLK4 1355/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 BRD9 1141/4885PLK4 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.